Shalini Subramaniam, Guy C. Toner, Martin R. Stockler, et al.
The authors conclude: The first planned interim analysis for safety (n=76) identified no safety concerns. The stage I analysis is anticipated mid-2021. This international randomised trial of chemotherapy for intermediate and poor-risk metastatic GCT is the first to include adults and children of both sexes. ClinicalTrials.gov: NCT02582697 Clinical trial information: NCT02582697
ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga
24-03-2021 09:47
ASCO and the oncology community are deeply saddened by the passingof JoséBaselga, MD, PhD, FASCO, on March 21, 2021, at age 61. Dr. Baselga died ofCreutzfeldt-Jakob disease,a rare fatal neurodegenerative disorder, according to his family.READ MORE
Pembrolizumab + Lenvatinib Significantly Improved PFS & OS vs CT in Advanced Endometrial Cancer Following Prior Platinum-Based CT
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma
08-02-2021 10:02
Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial MORE INFO